Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance

Neurology. 2012 Feb 14;78(7):507-8. doi: 10.1212/WNL.0b013e318246d6d8. Epub 2012 Feb 1.

Authors

Nicholas F Blair¹, Bruce J Brew, Jean-Pierre Halpern

Affiliation

¹ Royal North Shore Hospital, Sydney, Australia.

PMID: 22302545
DOI: 10.1212/WNL.0b013e318246d6d8

No abstract available

Publication types

Case Reports

MeSH terms

Anti-Inflammatory Agents / therapeutic use
Antibodies, Monoclonal, Humanized / adverse effects*
Antibodies, Monoclonal, Humanized / therapeutic use
Electroencephalography
Female
Humans
Immune Reconstitution Inflammatory Syndrome / complications
Interferon-beta / therapeutic use
JC Virus / immunology
Magnetic Resonance Imaging
Methylprednisolone / therapeutic use
Middle Aged
Multiple Sclerosis, Relapsing-Remitting / complications
Multiple Sclerosis, Relapsing-Remitting / drug therapy
Natalizumab
Posterior Leukoencephalopathy Syndrome / chemically induced*

Substances

Anti-Inflammatory Agents
Antibodies, Monoclonal, Humanized
Natalizumab
Interferon-beta
Methylprednisolone